Cancer is one of the leading killer diseases in the world and has a wide impact on many lives. It also manifests in various different types and can affect any part of the body including liver, lungs, throat, skin and many other organs. This is why researchers are consistently studying different types of cancers and how they can effectively treat and manage the disease. They often post their studies to open room for more tests and insights from other professional doctors. The latest cancer research has revealed new breakthroughs that are expected to enhance therapeutic treatment of tumors. The p53 is a gene that has been found to thwart cancer tumors directly as it regulates the activities of a protein known to suppress tumors growths.
P53 and tumor suppression
P53 is now a tumor-suppressing gene that will hopefully revolutionize the production of immunotherapy drugs formulated to deal with lung cancer. This gene was shown (in a research study) to block the off-switch that attacks T-cells. T-cells are the body’s key warriors of the immune system and also influence many other body functions including activities of mitochondria. A unique attack on the T-cells causes them to be inactive and allow tumors to thrive. The p53 was seen to directly regulate special proteins that cause this attack on T-cells. By reducing them, it minimizes the impact and allows T-cells to do their function of combating various diseases and attacks on the immune system. Mitochondria is tasked with converting food into ATP which is a special energy used up in the cells (Jason Hope). Each cell contains the complete DNA information required for all the processes and activities it is subjected to including how it grows and what it does. P53 gene by regulating the proteins that attack T-cells can therefore be optimized to significantly reduce these proteins and give T-cells a chance to suppress tumors as much as possible.
168-Tumor Suppressor p53
The research impacts
A group of researchers at University-of-Texas-MD Anderson-Cancer-Center reported in the Journal-of-the-National-Cancer-Institute are currently in a pre-clinical test of developing a new replacement of the gene once it fails. This will ensure the role of immune protection is protected whenever the p53 gene is ineffective. In about 43% of patients of lung cancer, p53 is suppressed, damaged or lacking. This is due to the encroachment of the tumors which increase the protein that attacks T-cells and continue to diminish the power of this immune protector. With this latest research on cancer, doctors anticipate a new way to enhance the use of immunotherapy drugs that suppress tumors. The identical gene being developed will be able to perform just as good as the natural p53 found in the body. The gene will then improve immune protection and can be optimized for maximum impact when treating lung cancer. P53 essentially interacts with and activates miR-34a (which is a micro RNA). MiR-34 directly stunts the expression of PDL1, the protein that attacks T-cells. As the researchers explained, failure of this gene directly causes full blown expression of the protein and this causes tumors to grow sporadically.
Although this research does not offer a comprehensive solution for treating lung cancer, it is a brilliant step towards the same. Inhibiting the growth of tumors is the hardest part of treating cancers and procedures like radiology and chemotherapy are often deemed quite risky. This new research offers a more natural way to suppress tumors and prevent its development.